2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Infusion, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Practice Models, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Measurable Residual Disease, ALL, Research, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

1550 ALL-TPFS3 identifies early treatment success and predicts survival after brexucabtagene autoleucel for adult B-cell acute lymphoblastic leukemia

Kriti Gera, MD, Bijal Shah, MD, MS2, Melanie Jugl3, Jongphil Kim, PhD4, Ghada Araji, MD5, Hana Qasim, Fellow6, Daniela Carolina Carolina Bravo Solarte, MD7, Jasmine Nadayil8, Corey Tesdahl9, Vaishnavi Jayakumar10, Fnu Amisha, MD11, Jessica Shostak, BS, DO, MA12, Ayda Soltanian, MD13, Amin Azem, MD14, Sayeef Mirza, BS, MPH, MD15, Alaa Ali, MD16, Nima Ghalehsari, MD17, Deepak Chellapandian, MD, MBBS18, Fabiana Perna, MD, PhD19, Leidy Isenalumhe, MD, MS20, Farhad Khimani, MD21, Frederick L. Locke, MD22, Michael D. Jain, MD, PhD23, Rawan Faramand, MD24, Aleksandr Lazaryan, MD MPH PhD25
1 University of South Florida/Mofffitt Cancer Center, Tampa, United States
2 Moffitt Cancer Center, Tampa, Florida, United States
3 Moffitt Cancer Center, Tampa, Florida, United States
4 Moffitt Cancer Center, Tampa, Florida, United States
5 Moffitt Cancer Center, Tampa, Florida, United States
6 Moffitt Cancer Center, Tampa, Florida, United States
7 Moffitt Cancer Center, Tampa, Florida, United States
8 University of South Florida/Mofffitt Cancer Center, Tampa, United States
9 University of South Florida/Mofffitt Cancer Center, Tampa, United States
10 University of South Florida/Mofffitt Cancer Center, Tampa, United States
11 Moffitt Cancer Center, Tampa, Florida, United States
12 University of South Florida/Mofffitt Cancer Center, Tampa, United States
13 Moffitt Cancer Center, Tampa, Florida, United States
14 Moffitt Cancer Center, Tampa, Florida, United States
15 Moffitt Cancer Center, Tampa, Florida, United States
16 Moffitt Cancer Center, Tampa, Florida, United States
17 Moffitt Cancer Center, Tampa, Florida, United States
18 Moffitt Cancer Center, Tampa, Florida, United States
19 Moffitt Cancer Center, Tampa, Florida, United States
20 Moffitt Cancer Center, Tampa, Florida, United States
21 Moffitt Cancer Center, Tampa, Florida, United States
22 Moffitt Cancer Center, Tampa, Florida, United States
23 Moffitt Cancer Center, Tampa, Florida, United States
24 Moffitt Cancer Center, Tampa, Florida, United States
25 Moffitt Cancer Center, Tampa, Florida, United States

Background: CD19-directed chimeric antigen receptor T-cell (CAR T) therapy with brexucabtagene autoleucel (brexu-cel) has transformed the treatment of relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL), achieving high response rates in heavily pretreated patients. However, substantial heterogeneity remains in treatment-related toxicity (CRS, ICANS), as well as in the durability of response. To capture both efficacy and clinically meaningful toxicity, we applied a composite endpoint of severe toxicity-free and progression-free survival at 3 months (ALL-TPFS3). A similar composite endpoint (TPFS6) has previously been validated in large B-cell lymphoma (Saha, Lazaryan et al., BMT 2026).

Methods: We performed a retrospective cohort study of 49 adult patients with r/r B-cell ALL who received brexu-cel at Moffitt Cancer Center between January 2018 and April 2025. ALL-TPFS3 was defined as the absence of any of the following events within 3 months of CAR T-cell infusion: (1) grade ≥3 CRS, (2) grade ≥3 ICANS, (3) failure to achieve MRD-negative complete remission (CR, CRi, or CRh) by clonoseq, (4) non-relapse mortality (NRM), or (5) prolonged severe hematologic toxicity, defined as grade 4 neutropenia and/or grade 4 thrombocytopenia present at Day +30 and persisting through Day +90. Patients with multiple qualifying events were assigned according to the earliest event. Logistic regression identified predictors of ALL-TPFS3. Three-month landmark analyses evaluated associations with OS and PFS.

Results: ALL-TPFS3 was achieved in 38.8% (19/49) of patients (95% CI, 25.2–53.8%). Among ALL-TPFS3 failures (n=30), severe ICANS (50.0%) was the most common qualifying event, followed by MRD-negative remission failure (26.7%), severe CRS (13.3%), prolonged severe hematologic toxicity (6.7%), and NRM (3.3%). Morphologic disease at infusion (56.7% vs 21.1%, p=0.038) and high-risk ALL-Hematotox (ALL-HT) (40.0% vs 5.3%, p=0.008) were associated with ALL-TPFS3 failure. Prior blinatumomab exposure was associated with higher odds of ALL-TPFS3 failure in univariate analysis (OR 3.43, p=0.045). On multivariable logistic regression, only disease status (morphologic disease vs MRD-positive only/MRD-negative) at infusion was independently associated with ALL-TPFS3 (OR=6.38, 95% CI 1.27–37.9; p=0.030). In the 3-month landmark OS analysis (n=45, excluding 4 patients who died or were lost to follow-up within the first 3 months), ALL-TPFS3 failure was associated with a more than 4-fold higher risk of death (HR=4.64, 95% CI 1.04–20.8; p=0.045; median OS ~3 yrs vs. not reached). This association remained independent of sex, LDH, and ALL-HT risk on multivariable Cox modeling (HR=11.9, 95% CI 2.35–60.6; p=0.003). A 3-month PFS landmark analysis (n=39, excluding 6 additional patients who progressed within the first 3 months) demonstrated a similar trend after adjustment for age, lymphodepletion regimen, disease status, prior alloHSCT, and bridging therapy (HR=3.66, 95% CI 0.92–14.5; p=0.065). Exploratory landmark analyses demonstrated differential effects of ALL‑TPFS3 components. Toxicity-related failure was associated with inferior OS (HR=11.3, p=0.005) but not PFS (HR=2.4, p=0.3), whereas MRD-negative remission failure predicted both inferior OS (HR=13.0, p=0.005) and markedly worse PFS (HR=88.2, p<0.001), suggesting that treatment-related toxicity and residual disease represent distinct contributors to early ALL‑TPFS3 failure.

Conclusion: In adult patients with r/r B-ALL treated with brexu-cel, ALL-TPFS3 identified a subgroup with substantially superior subsequent survival. Morphologic disease at infusion was the strongest predictor of ALL-TPFS3 failure, supporting disease burden reduction before CAR T.  Differential outcomes among toxicity- and MRD-related failures further suggest that treatment-related toxicity and residual disease represent distinct but complementary determinants of early treatment success, establishing ALL-TPFS3 as a clinically meaningful endpoint for future studies and therapeutic optimization strategies.

 

Kriti Gera, MD: No relevant conflicts of interest to declare.